TY - JOUR
T1 - A prostate cancer vaccine comprising whole cells secreting IL-7, effective against subcutaneous challenge, requires local GM-CSF for intra-prostatic efficacy
AU - Schroten-Leof, Caroline
AU - de Riddler, Corinna
AU - Reneman, Suzanne
AU - Crezee, Marije
AU - Dalgleish, Angus
AU - Todryk, Stephen
AU - Bangma, Chris
AU - Kraaij, Robert
PY - 2009
Y1 - 2009
N2 - A panel of cytokine-secreting RM-9 prostate cancer cells were tested as whole cell vaccines to determine their capacity to evoke an anti-prostate cancer immune response. In our model, vaccines secreting mGM-CSF or mIL-7 resulted in the highest increase in circulating T lymphocytes after vaccination, prolonged survival and, in a proportion of animals, tumor-free survival. Anti-tumor effects were more evident after a subcutaneous RM-9 challenge than after an intraprostatic challenge. However, when the RM-9/mGM-CSF cell line was used as intraprostatic tumor challenge, protection after RM-9/mIL-7 vaccination was restored.
AB - A panel of cytokine-secreting RM-9 prostate cancer cells were tested as whole cell vaccines to determine their capacity to evoke an anti-prostate cancer immune response. In our model, vaccines secreting mGM-CSF or mIL-7 resulted in the highest increase in circulating T lymphocytes after vaccination, prolonged survival and, in a proportion of animals, tumor-free survival. Anti-tumor effects were more evident after a subcutaneous RM-9 challenge than after an intraprostatic challenge. However, when the RM-9/mGM-CSF cell line was used as intraprostatic tumor challenge, protection after RM-9/mIL-7 vaccination was restored.
KW - immunotherapy
KW - whole cell vaccine
KW - cytokines
KW - prostate cancer
KW - MPR-model
UR - https://www.scopus.com/pages/publications/58149313844
U2 - 10.1007/s00262-008-0560-z
DO - 10.1007/s00262-008-0560-z
M3 - Article
SN - 0340-7004
SN - 1432-0851
VL - 58
SP - 373
EP - 381
JO - Cancer Immunology Immunotherapy
JF - Cancer Immunology Immunotherapy
IS - 2
ER -
